首页 > 癌症生物学与医学（英文版） > IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash:preclinical and clinical responses

IL-17A blockade alleviates immune checkpoint inhibitor-associated psoriasiform rash:preclinical and clinical responses

导出在线阅读解读下载全文终端阅读

二维码有效期 120s

点击刷新

注：终端设备浏览有效期：

学术成果认领

翻译打印收藏纠错

摘要Psoriasiform rash is a notable immune-related cutaneous adverse event(ircAE)accounting for approximately 5％ of all ircAEs1,2.Patients with cancer and pre-existing psoriasis face elevated risk of disease recurrence or exacerbation after receiving immune checkpoint inhibitors(ICIs).A European multicenter study has reported a reactivation rate of 28.7％ in this population3.ICIs also trigger de novo psoriatic lesions,which mirror conventional lesion subtypes(plaque,guttate,erythrodermic,or pustular),and 20％–30％ of patients develop psoriatic arthritis4.

作者 Yuli Ruan ^[1] Mengde Shi ^[1] Yue Ma ^[1] Bojun Wang ^[1] Ming Ma ^[2] Tianjiao Dang ^[2] Yanqiao Zhang ^[3] Chao Liu ^[3] 学术成果认领

作者单位 Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150001,China;Clinical Research Center for Colorectal Cancer in Heilongjiang,Harbin 150001,China;Key Laboratory of Tumor Immunology in Heilongjiang,Harbin 150001,China ^[1] Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150001,China;Key Laboratory of Tumor Immunology in Heilongjiang,Harbin 150001,China ^[2] Department of Gastrointestinal Medical Oncology,Harbin Medical University Cancer Hospital,Harbin 150001,China;Clinical Research Center for Colorectal Cancer in Heilongjiang,Harbin 150001,China;Key Laboratory of Tumor Immunology in Heilongjiang,Harbin 150001,China;Key Laboratory of Preservation of Human Genetic Resources and Disease Control in China(Harbin Medical University),Ministry of Education,Harbin 150001,China ^[3]

关键词 Immune checkpoint inhibitors immune-related cutaneous adverse events psoriasiform rash IL-17A secukinumab

栏目名称

LETTER

DOI 10.20892/j.issn.2095-3941.2025.0344

发布时间 2025-12-15（万方平台首次上网日期，不代表论文的发表时间）

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交